Adage Capital Partners’s Neurocrine Biosciences NBIX Stock Holding History

Adage Capital Partners’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-341,578	Closed	-$42.9M	–	947
2025 Q2	$42.9M	Buy	+341,578	New	+$39.2M	0.07%	270
2022 Q3	–	Sell	-105,000	Closed	-$10.2M	–	1091
2022 Q2	$10.2M	Buy	105,000 +20,000	+24%	+$1.85M	0.02%	663
2022 Q1	$7.97M	Sell	85,000 -352,000	-81%	-$29.8M	0.02%	755
2021 Q4	$37.2M	Buy	+437,000	New	+$40.2M	0.07%	298
2019 Q4	–	Sell	-62,000	Closed	-$5.59M	–	748
2019 Q3	$5.59M	Buy	+62,000	New	+$5.79M	0.01%	618
2019 Q1	–	Sell	-8,000	Closed	-$571K	–	723
2018 Q4	$571K	Sell	8,000 -18,000	-69%	-$1.72M	﹤0.01%	689
2018 Q3	$3.2M	Sell	26,000 -126,000	-83%	-$14.3M	0.01%	661
2018 Q2	$14.9M	Buy	+152,000	New	+$13.6M	0.03%	478
2014 Q2	–	Sell	-136,286	Closed	-$2.19M	–	725
2014 Q1	$2.19M	Buy	+136,286	New	+$2.33M	0.01%	640

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Adage Capital Partners's NBIX Position: Q3 2025 in Review

Adage Capital Partners sold out of Neurocrine Biosciences (NBIX) in Q3 2025, closing a stake of 341,578 shares — an estimated $42.9M sold.

Adage Capital Partners first reported a position in NBIX in Q1 2014 and held it in 9 quarters. The position peaked at $42.9M in Q2 2025. 650 funds tracked by Wall St. Rank hold NBIX as of Q3 2025.

Adage Capital Partners reported no remaining Neurocrine Biosciences position as of Q3 2025 after selling out during the quarter.
Adage Capital Partners sold 341,578 Neurocrine Biosciences shares in Q3 2025, an estimated $42.9M.
Adage Capital Partners first reported a position in Neurocrine Biosciences in Q1 2014 and held it in 9 quarters.
Adage Capital Partners's Neurocrine Biosciences position peaked at $42.9M in Q2 2025.
650 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2025.

Based on Adage Capital Partners's 13F filing for Q3 2025, filed 14 Nov 2025.